688266 泽璟制药-U
交易中 07-27 10:23:53
资讯
新帖
简况
富国基金朱少醒旗下基金二季报出炉！中际旭创(300308.SZ)、泽璟制药(688266.SH)首度进入前十大重仓股
智通财经 · 07-21
富国基金朱少醒旗下基金二季报出炉！中际旭创(300308.SZ)、泽璟制药(688266.SH)首度进入前十大重仓股
泽璟制药（688266）披露股票交易异常波动公告，7月3日股价上涨4.91%
证券之星 · 07-03
泽璟制药（688266）披露股票交易异常波动公告，7月3日股价上涨4.91%
7月3日泽璟制药（688266）龙虎榜数据：机构净买入4.36亿元，北向资金净卖出3926.97万元
证券之星 · 07-03
7月3日泽璟制药（688266）龙虎榜数据：机构净买入4.36亿元，北向资金净卖出3926.97万元
泽璟制药（688266）披露2025年年度股东会决议公告，6月29日股价上涨7.13%
证券之星 · 06-29
泽璟制药（688266）披露2025年年度股东会决议公告，6月29日股价上涨7.13%
每周股票复盘：泽璟制药（688266）2025年年度股东会各项议案均获通过
证券之星 · 06-28
每周股票复盘：泽璟制药（688266）2025年年度股东会各项议案均获通过
新股消息 | 泽璟制药(688266.SH)港股IPO招股书失效
智通财经 · 06-22
新股消息 | 泽璟制药(688266.SH)港股IPO招股书失效
每周股票复盘：泽璟制药（688266）吉卡昔替尼获准治重度斑秃
证券之星 · 06-20
每周股票复盘：泽璟制药（688266）吉卡昔替尼获准治重度斑秃
泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗重度斑秃适应症上市申请获得批准
智通财经 · 06-15
泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗重度斑秃适应症上市申请获得批准
每周股票复盘：泽璟制药（688266）ZG005/ZG006临床进展亮相ASCO
证券之星 · 06-07
每周股票复盘：泽璟制药（688266）ZG005/ZG006临床进展亮相ASCO
泽璟制药（688266）披露2025年年度股东会通知，6月1日股价下跌0.31%
证券之星 · 06-01
泽璟制药（688266）披露2025年年度股东会通知，6月1日股价下跌0.31%
股市必读：泽璟制药（688266）5月29日披露最新机构调研信息
证券之星 · 06-01
股市必读：泽璟制药（688266）5月29日披露最新机构调研信息
每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β III期临床达主要终点
证券之星 · 05-10
每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β III期临床达主要终点
泽璟制药（688266）披露注射用人促甲状腺素β III期临床试验达到预设主要终点，5月8日股价下跌2.92%
证券之星 · 05-08
泽璟制药（688266）披露注射用人促甲状腺素β III期临床试验达到预设主要终点，5月8日股价下跌2.92%
每周股票复盘：泽璟制药（688266）Q1净利增2338%
证券之星 · 05-02
每周股票复盘：泽璟制药（688266）Q1净利增2338%
图解泽璟制药一季报：第一季度单季净利润同比增长2338.37%
证券之星 · 04-28
图解泽璟制药一季报：第一季度单季净利润同比增长2338.37%
每周股票复盘：泽璟制药（688266）将参加2026年5月11日科创板集体业绩说明会
证券之星 · 04-26
每周股票复盘：泽璟制药（688266）将参加2026年5月11日科创板集体业绩说明会
泽璟制药（688266）披露将参加2025年度制药行业集体业绩说明会，4月23日股价下跌3.14%
证券之星 · 04-23
泽璟制药（688266）披露将参加2025年度制药行业集体业绩说明会，4月23日股价下跌3.14%
泽璟制药（688266）披露股东及董事、高级管理人员减持股份结果公告，4月20日股价上涨1.21%
证券之星 · 04-20
泽璟制药（688266）披露股东及董事、高级管理人员减持股份结果公告，4月20日股价上涨1.21%
每周股票复盘：泽璟制药（688266）高管与股东减持股份
证券之星 · 04-19
每周股票复盘：泽璟制药（688266）高管与股东减持股份
泽璟制药：4月16日董事长ZELIN SHENG(盛泽林)减持股份合计27.39万股
证券之星 · 04-17
泽璟制药：4月16日董事长ZELIN SHENG(盛泽林)减持股份合计27.39万股
加载更多
公司概况
公司名称：
苏州泽璟生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-01-23
主营业务：
苏州泽璟生物制药股份有限公司的主营业务是创新型小分子及生物制剂疗法的发现、研发及商业化。公司的主要产品是甲苯磺酸多纳非尼片、盐酸吉卡昔替尼片、重组人凝血酶、注射用人促甲状腺素β。在血液病及止血领域，泽普凝为中国唯一采用重组DNA技术研发并成功上市的重组人凝血酶。
发行价格：
33.76
{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"泽璟制药-U","latestPrice":139.48,"timestamp":1785119033000,"preClose":135.95,"halted":0,"volume":2985888,"delay":0,"changeRate":0.026,"floatShares":265000000,"shares":265000000,"eps":1.8811,"marketStatus":"交易中","change":3.53,"latestTime":"07-27 10:23:53","open":134.09,"high":142.5,"low":134.09,"amount":414000000,"amplitude":0.0619,"askPrice":139.71,"askSize":2,"bidPrice":139.5,"bidSize":4,"shortable":0,"etf":0,"ttmEps":1.8811,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1785123000000},"marketStatusCode":2,"adr":0,"adjPreClose":135.95,"symbolType":"stock_kcb","openAndCloseTimeList":[[1785115800000,1785123000000],[1785128400000,1785135600000]],"highLimit":149.55,"lowLimit":122.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":21.01,"roa":"--","peRate":74.148105,"roe":"45.29%","epsLYR":-0.62,"committee":-0.277778,"marketValue":36921000000,"turnoverRate":0.0113,"status":0,"floatMarketCap":36921000000},"requestUrl":"/m/hq/s/688266","defaultTab":"news","newsList":[{"id":"2653322764","title":"富国基金朱少醒旗下基金二季报出炉！中际旭创(300308.SZ)、泽璟制药(688266.SH)首度进入前十大重仓股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653322764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653322764?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:08","pubTimestamp":1784621322,"startTime":"0","endTime":"0","summary":"截至二季度末，中际旭创、泽璟制药首度进入该基金的前十大重仓股，分别成为第六大、第七大重仓股。同时，中国平安、滨江集团再度进入该基金的前十大重仓股，徐工机械、紫金矿业、瑞丰新材、贵州茅台集体退出该基金的前十大重仓股。截至二季度末，该基金继续重仓持有宁波银行，并且持股数量与上个季度保持不变。截至2026年二季度末，该基金已连续24个季度重仓宁波银行，持仓市值达14.85亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","IE0034224299.USD","LU0327786744.USD","LU2778985437.USD","91530","LU2476274308.USD","LU0708995583.HKD","LU0320764599.SGD","300308","LU0164939612.USD","LU1770034418.SGD","LU0348735423.USD","SGXZ49509284.SGD","LU0039217434.USD","LU1064130708.USD","LU0210526637.USD","LU0348827113.USD","IE0032431581.USD","LU1251922891.USD","BK1191","LU2476274720.SGD","SGXZ81163826.USD","LU1303224171.USD","LU0634319403.HKD","LU1655091616.SGD","LU2495084118.USD","LU2399975544.HKD","LU2177674079.SGD","LU1720050803.USD","LU2148510915.USD","SG9999011746.SGD","LU1794554557.SGD","LU1979443071.USD","HK0000320223.HKD","BK0167","LU1580142542.USD","LU1781817850.SGD","688266","LU0469268626.HKD","LU0871576103.HKD","LU0231483743.USD","LU1997245177.USD","LU0572944931.SGD","LU2008162690.USD","01477","LU1961090484.USD","LU1820825898.SGD","LU1719994722.HKD","LU1064131003.USD","LU0082770016.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648661537","title":"泽璟制药（688266）披露股票交易异常波动公告，7月3日股价上涨4.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648661537?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:04","pubTimestamp":1783087465,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，泽璟制药报收于143.0元，较前一交易日上涨4.91%，最新总市值为378.53亿元。该股当日开盘135.0元，最高146.02元，最低125.69元，成交额达19.35亿元，换手率为5.45%。近日，泽璟制药发布《股票交易异常波动公告》。公告显示，公司股票交易连续3个交易日内日收盘价格涨幅偏离值累计达到30%，构成股票交易异常波动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300045210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","688266","BK1574","01477","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648969650","title":"7月3日泽璟制药（688266）龙虎榜数据：机构净买入4.36亿元，北向资金净卖出3926.97万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648969650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648969650?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:44","pubTimestamp":1783071878,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月3日公布的交易公开信息显示，泽璟制药因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月3日收盘，泽璟制药报收于143.0元，上涨4.91%，换手率5.45%，成交量14.43万手，成交额19.35亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入4.36亿元，北向资金合计净卖出3926.97万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300032992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","688266","BK1574","BK0239","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378221","title":"泽璟制药（688266）披露2025年年度股东会决议公告，6月29日股价上涨7.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647378221?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:06","pubTimestamp":1782727603,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘，泽璟制药报收于114.41元，较前一交易日上涨7.13%，最新总市值为302.85亿元。公司于近日披露《泽璟制药2025年年度股东会决议公告》。出席会议的股东及代理人共554人，代表有表决权股份总数的52.1932%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900029041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK1191","BK0239","688266","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646315498","title":"每周股票复盘：泽璟制药（688266）2025年年度股东会各项议案均获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2646315498","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646315498?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:39","pubTimestamp":1782589151,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，泽璟制药报收于106.8元，较上周的89.69元上涨19.08%。本周，泽璟制药6月26日盘中最高价报109.36元。本周关注点公司公告汇总：泽璟制药2025年年度股东会各项议案均获通过，出席股东及代理人共554人，代表有表决权股份总数的52.1932%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","01477","688266","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645744010","title":"新股消息 | 泽璟制药(688266.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2645744010","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645744010?lang=zh_cn&edition=full","pubTime":"2026-06-22 10:53","pubTimestamp":1782096824,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，苏州泽璟生物制药股份有限公司(简称：泽璟制药，688266.SH)于2025年12月19日所递交的港股招股书满6个月，于2026年6月19日失效，递表时中金公司为其独家保荐人。招股书显示，泽璟制药为一家综合生物制药企业，专注于创新型小分子及生物制剂疗法的发现、研发及商业化，策略聚焦于肿瘤学、自身免疫性疾病、止血/血液病领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1574","VXUS","BK4585","BK1191","BK0239","BK4588","688266","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063790","title":"每周股票复盘：泽璟制药（688266）吉卡昔替尼获准治重度斑秃","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063790","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644063790?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:28","pubTimestamp":1781893693,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，泽璟制药报收于89.69元，较上周的92.88元下跌3.43%。本周关注点公司公告汇总：盐酸吉卡昔替尼片治疗成人重度斑秃适应症获批上市。公司公告汇总泽璟制药关于自愿披露盐酸吉卡昔替尼片治疗重度斑秃适应症上市申请获得批准的公告苏州泽璟生物制药股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》，公司自主研发的盐酸吉卡昔替尼片用于治疗成人重度斑秃的上市申请获得批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK1191","BK1574","BK0239","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643272432","title":"泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗重度斑秃适应症上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643272432","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643272432?lang=zh_cn&edition=full","pubTime":"2026-06-15 18:16","pubTimestamp":1781518615,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药 发布公告，近日，公司收到国家药品监督管理局核准签发的《药品注册证书》，公司自主研发的盐酸吉卡昔替尼片用于治疗成人重度斑秃的上市申请获得批准。这是继用于治疗中、高危骨髓纤维化的适应症获批后，盐酸吉卡昔替尼片第二个获批上市的适应症，也是盐酸吉卡昔替尼片首个获批的治疗免疫炎症性疾病的临床适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641122074","title":"每周股票复盘：泽璟制药（688266）ZG005/ZG006临床进展亮相ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2641122074","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641122074?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:00","pubTimestamp":1780768845,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，泽璟制药报收于90.67元，较上周的99.93元下跌9.27%。本周，泽璟制药6月1日盘中最高价报105.59元。公司公告汇总：泽璟制药将于2026年6月26日召开2025年年度股东会，采用现场与网络投票结合方式。泽璟制药关于自愿披露ZG005和ZG006在2026年美国临床肿瘤学会年会发布临床数据及最新进展的公告苏州泽璟生物制药股份有限公司自主研发的新药ZG005和ZG006的临床研究数据及最新进展在2026年美国临床肿瘤学会年会上发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640898950","title":"泽璟制药（688266）披露2025年年度股东会通知，6月1日股价下跌0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640898950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640898950?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:15","pubTimestamp":1780323318,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，泽璟制药报收于99.62元，较前一交易日下跌0.31%，最新总市值为263.7亿元。近日，泽璟制药发布《关于召开2025年年度股东会的通知》。公告显示，苏州泽璟生物制药股份有限公司将于2026年6月26日召开2025年年度股东会，会议采取现场投票与网络投票相结合的方式，股权登记日为2026年6月22日。会议审议包括2025年年度报告、董事会工作报告、利润分配预案、续聘2026年度审计机构、董事薪酬标准及薪酬管理制度等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100040858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640851849","title":"股市必读：泽璟制药（688266）5月29日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2640851849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640851849?lang=zh_cn&edition=full","pubTime":"2026-06-01 03:42","pubTimestamp":1780256530,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，泽璟制药报收于99.93元，上涨3.23%，换手率1.72%，成交量4.54万手，成交额4.41亿元。当日关注点来自交易信息汇总：5月29日主力资金净流入448.35万元，占总成交额1.02%。来自机构调研要点：泽璟制药将在2026年ASCO年会公布ZG005联合贝伐珠单抗用于晚期肝细胞癌一线治疗的Ⅱ期临床研究数据，该研究入选大会口头报告。注射用ZG006联合瀚森制药HS-20093治疗广泛期小细胞肺癌的临床试验已获国家药监局批准，公司正推进合作事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634741496","title":"每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2634741496","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634741496?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:29","pubTimestamp":1778351350,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：注射用人促甲状腺素β III期临床试验达到预设主要终点。公司公告汇总泽璟制药关于自愿披露注射用人促甲状腺素β III期临床试验达到预设主要终点的公告苏州泽璟生物制药股份有限公司自主研发的注射用人促甲状腺素βIII期临床试验达到预设主要终点，该试验用于评价其在分化型甲状腺癌患者术后放射性碘清甲治疗的有效性和安全性。注射用人促甲状腺素β已于2026年1月获批用于甲状腺癌术后随访中的协同诊断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633300431","title":"泽璟制药（688266）披露注射用人促甲状腺素β III期临床试验达到预设主要终点，5月8日股价下跌2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633300431","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633300431?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:35","pubTimestamp":1778232935,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于自愿披露注射用人促甲状腺素β III期临床试验达到预设主要终点的公告》。公告显示，苏州泽璟生物制药股份有限公司自主研发的注射用人促甲状腺素βIII期临床试验达到预设主要终点，该试验用于评价其在分化型甲状腺癌患者术后放射性碘清甲治疗的有效性和安全性。注射用人促甲状腺素β已于2026年1月获批用于甲状腺癌术后随访中的协同诊断。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800031507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632420036","title":"每周股票复盘：泽璟制药（688266）Q1净利增2338%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632420036","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632420036?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:06","pubTimestamp":1777665974,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，泽璟制药报收于104.0元，较上周的97.1元上涨7.11%。本周，泽璟制药4月30日盘中最高价报108.73元。股本股东变化截至2026年3月31日，泽璟制药股东户数为8344.0户，较2月28日减少1685.0户，减幅为16.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630237034","title":"图解泽璟制药一季报：第一季度单季净利润同比增长2338.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630237034","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630237034?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:23","pubTimestamp":1777371783,"startTime":"0","endTime":"0","summary":"证券之星消息，泽璟制药2026年一季报显示，一季度公司主营收入9.05亿元，同比上升440.07%；归母净利润6.33亿元，同比上升2338.37%；扣非净利润6.32亿元，同比上升1362.4%；负债率53.56%，投资收益3.45万元，财务费用-111.81万元，毛利率97.01%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630804451","title":"每周股票复盘：泽璟制药（688266）将参加2026年5月11日科创板集体业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2630804451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630804451?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:54","pubTimestamp":1777146851,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，泽璟制药报收于97.1元，较上周的98.8元下跌1.72%。本周，泽璟制药4月20日盘中最高价报103.66元。本周关注点公司公告汇总：泽璟制药将参加2026年5月11日举行的科创板集体业绩说明会。投资者可于2026年4月29日至5月8日16:00前通过上证路演中心网站或公司邮箱提前提问。公司将就2025年年度报告涉及的经营成果、财务状况等投资者关注问题进行解答。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830726","title":"泽璟制药（688266）披露将参加2025年度制药行业集体业绩说明会，4月23日股价下跌3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830726","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629830726?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:05","pubTimestamp":1776953123,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，泽璟制药报收于98.0元，较前一交易日下跌3.14%，最新总市值为259.41亿元。近日，泽璟制药发布《关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公告显示，公司将于2026年5月11日15:00-17:00通过上证路演中心网络互动方式参加由上海证券交易所主办的上述集体业绩说明会。公司将就2025年年度报告涉及的经营成果、财务状况等投资者关注问题进行解答。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300061779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK1574","BK0239","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628746118","title":"泽璟制药（688266）披露股东及董事、高级管理人员减持股份结果公告，4月20日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628746118","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628746118?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:32","pubTimestamp":1776677526,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘，泽璟制药报收于100.0元，较前一交易日上涨1.21%，最新总市值为264.71亿元。公司于近日披露《股东及董事、高级管理人员减持股份结果公告》。公告显示，本次减持计划实施前，ZELIN SHENG（盛泽林）持有公司18.8549%股份，宁波泽奥持有6.2335%股份。2026年2月14日，公司披露减持计划，ZELIN SHENG（盛泽林）拟减持不超过273,907股，宁波泽奥拟减持不超过2,475,090股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000024454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628759721","title":"每周股票复盘：泽璟制药（688266）高管与股东减持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628759721","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628759721?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:12","pubTimestamp":1776539529,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，泽璟制药报收于98.8元，较上周的97.77元上涨1.05%。本周，泽璟制药4月16日盘中最高价报102.87元。泽璟制药当前最新总市值261.53亿元，在化学制药板块市值排名16/150，在两市A股市值排名832/5198。股本股东变化：宁波泽奥创业投资合伙企业减持247.51万股，持股比例降至5.2985%。股本股东变化股东增减持4月17日公告显示，宁波泽奥创业投资合伙企业于2026年4月2日至4月15日期间合计减持152.05万股，占公司总股本的0.5744%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628120829","title":"泽璟制药：4月16日董事长ZELIN SHENG(盛泽林)减持股份合计27.39万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628120829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628120829?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:01","pubTimestamp":1776423664,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月17日市场公开信息、上市公司公告及交易所披露数据整理，泽璟制药最新董监高及相关人员股份变动情况：2026年4月16日公司董事长,总经理ZELIN SHENG(盛泽林)共减持公司股份27.39万股，占公司总股本为0.1035%。泽璟制药近半年内的董监高及核心技术人员增减持详情如下：泽璟制药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入616.97万，融资余额增加；融券净流出2112.0，融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700037890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785119041332,"stockEarnings":[{"period":"1week","weight":0.0449},{"period":"1month","weight":0.3652},{"period":"3month","weight":0.4001},{"period":"6month","weight":0.5484},{"period":"1year","weight":0.1071},{"period":"ytd","weight":0.4666}],"compareEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":-0.0722},{"period":"3month","weight":-0.0651},{"period":"6month","weight":-0.0778},{"period":"1year","weight":0.0578},{"period":"ytd","weight":-0.039}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8344人(较上一季度减少16.80%)","perCapita":"31724股","listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","registeredCapital":"26470万元","survey":" 苏州泽璟生物制药股份有限公司的主营业务是创新型小分子及生物制剂疗法的发现、研发及商业化。公司的主要产品是甲苯磺酸多纳非尼片、盐酸吉卡昔替尼片、重组人凝血酶、注射用人促甲状腺素β。在血液病及止血领域，泽普凝为中国唯一采用重组DNA技术研发并成功上市的重组人凝血酶。","listedPrice":33.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泽璟制药-U(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泽璟制药-U(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泽璟制药-U,688266,泽璟制药-U股票,泽璟制药-U股票老虎,泽璟制药-U股票老虎国际,泽璟制药-U行情,泽璟制药-U股票行情,泽璟制药-U股价,泽璟制药-U股市,泽璟制药-U股票价格,泽璟制药-U股票交易,泽璟制药-U股票购买,泽璟制药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泽璟制药-U(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泽璟制药-U(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}